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Background Extra-articular manifestations (EAMs) are common in patients with rheumatoid arthritis (RA). Cardiac EAMs are
rare but may cause complete heart block and damage to the heart valves.
...................................................................................................................................................................................................
Case summary We present the case of a middle-aged woman with long-standing RA and EAMs as the most prominent symptoms.
The patient experienced complete atrioventricular heart block and developed nodular vegetations affecting the mi-
tral valve, ultimately leading to severe mitral regurgitation and valve replacement.
...................................................................................................................................................................................................
Discussion The diagnosis of cardiac EAMs in RA may be challenging for the clinicians. Symptoms and findings may mimic more
common conditions such as malignancy and infectious endocarditis. A multidisciplinary approach is of paramount
importance in order to make an early diagnosis and to provide optimal treatment to patients with RA and cardiac
complications.
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Introduction
Rheumatoid arthritis (RA) is a chronic debilitating inflammatory dis-
ease that primarily affects synovial joints and surrounding tissues.1
Yet, up to 40% of the patients experience extra-articular manifesta-
tions (EAMs).2 Extra-articular manifestations are more frequently
seen in patients with positive rheumatoid factor (RF) and the pres-
ence of anti-cyclic citrullinated peptide antibodies (ACPA). Extra-
articular manifestations are associated with a more progressive dis-
ease and increased mortality.3 The most common cardiac EAMs are
Learning points
• Mitral valvulitis leading to severe mitral regurgitation is a rare
extra-articular manifestation of rheumatoid arthritis.
• Early recognition of cardiac complications as signs of extra-ar-
ticular manifestations in rheumatoid arthritis may lead to a
more aggressive treatment strategy in patients who otherwise
are in remission.
• The best management of cardiac complications in a patient
with rheumatoid arthritis remains difficult and requires a multi-
disciplinary approach.
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.pericarditis, non-specific endocarditis, and myocarditis. These cardiac
complications are, however, rarely clinically apparent.1,4 In general,
the subcutaneous rheumatoid nodule is the most common EAM,
with a prevalence of 30% in RA.5–7 Rheumatoid nodules may affect
any organ and contribute to organ damage. Cardiac involvement by
rheumatoid nodules is rare, but nodules may develop in the pericar-
dium, myocardium, and valvular structures causing valve insufficiency,
thrombo-embolic complications, and heart block due to damage to
the conduction system.4 In the present report, we describe a rare
case of mitral valvulitis as a severe systemic manifestation of RA in an
RF-positive female patient in the absence of joint symptoms.
Timeline
Case presentation
A 45-year-old Caucasian female with a medical history of seroposi-
tive non-erosive RA presented in the cardiac outpatient clinic for a
routine echocardiographic evaluation, due to small nodules on the
mitral valve, detected 1 year before. Fourteen years earlier, at the
time of diagnosis, the patient met the 2010 American College of
Rheumatology (ACR)/European League Against Rheumatism
(EULAR) classification criteria for RA. Disease-modifying anti-
rheumatic drug (DMARD) treatment with methotrexate achieved
sustained remission throughout the years, with no swollen or
tender joints. Repeated conventional radiographs were without
signs of erosive joint disease. The main symptom was recurrent
episodes of scleritis, treated with glucocorticoids and treatment
was escalated with infliximab, a monoclonal antibody of tumour
necrosis factor (anti-TNF).
One year prior to presentation, the patient was admitted to the
emergency department with complete atrioventricular heart block
and underwent pacemaker implantation. In the same setting, a cardiac
magnetic resonance scan showed severe inflammatory activity in the
region of the mitral valve. Additional echocardiography showed small
....................................................................................................................................................................................................................
Time Event Treatment
June, 2003 Diagnosed with seropositive, anti-cyclic citrullinated peptide antibodies-nega-
tive rheumatoid arthritis (In retrospective, meeting 9/10 of 2010 American
College of Rheumatology (ACR)/European League Against Rheumatism
(EULAR) classification criteria)
Methotrexate
2003, 2007, 2015, and 2016 Scleritis Oral and local glucocorticoid
March, 2016 Third-degree heart block
Cardiac magnetic resonance imaging: Inflammatory activity in the region of the
mitral valve.
Echocardiography: Clinically insignificant nodules were noticed on the mitral valve.
Pacemaker-implantation
April, 2016 Scleritis Infliximab added
April, 2017 Scheduled 1-year follow-up. Onset of exertional dyspnoea [New York Heart
Association (NYHA) II].
Echocardiography: Severe thickening of the mitral leaflets. Large nodular vege-
tations involving the chordae tendinea.
Trivial mitral regurgitation.
FDG-PET/CT: Severe inflammatory activity at the mitral valve involving the
chordae tendinea.
Warfarin
June, 2017 Cardiac findings were considered consistent with severe inflammatory activity
and extra-articular manifestation, secondary to RA.
The immunosuppressive treatment was
intensified by starting Rituximab and
discontinuing infliximab.
September, 2017 Symptoms: Dyspnoea progression (NYHA III)
Echocardiography:
Regression in the valve lesions but severe mitral regurgitation due to fibrosis of
the valves.
Normal C-reactive protein, no tender or swollen joints.
Furosemide, 40 mg daily, was added to
treat symptoms of heart failure.
March, 2018 Echocardiography: Increasing mitral regurgitation volume. Hyperdynamic left
ventricle.
Surgery with insertion of a mechanical
mitral valve.
September, 2020 Echocardiography: Normal function of the mechanical valve prosthesis, and
normal left ventricular ejection fraction. Physical examination was unremark-
able and the patient was asymptomatic.
















nodular vegetations on the mitral valve without clinical significance.
The patient did not have any other comorbidities. The patient was
therefore scheduled for a routine follow-up visit 1 year later.
At examination 1 year later, the patient complained of exertional
dyspnoea [New York Heart Association (NYHA) II]. Physical examin-
ation revealed no signs of heart failure. A new echocardiography
revealed severe structural changes of the mitral valve with thickening
of the leaflets and enlargement of the valvular vegetations, involving
the chordae tendineae. Morphologically, the vegetations had a nodular
shape, were tightly attached to the surface of the valve, and displayed
no independent movement (Figure 1). A whole-body FDG-positron
emission tomography (PET)-scan revealed severe inflammatory activ-
ity at the mitral valve, involving the chordae tendineae (Figure 2).
To prevent thrombus formation on the damaged valve, anticoagu-
lant treatment with warfarin was started. This treatment did not alter
the size of the vegetations at follow-up 2 months later. The diagnosis
of RA was thoroughly evaluated, and a variety of differential diagno-
ses were considered (please refer to Table 1). Despite normal body
temperature, endocarditis with a low-virulence pathogen was consid-
ered due to long-term immunosuppressive treatment. Serologic test-
ing for multiple bacterial and viral infections was performed (please
Figure 1 Transoesophageal echocardiogram of the mitral valve. Vegetations are nodular shaped, tightly attached to the surface of the valve, and
without independent movement.
Figure 2 Positron emission tomography of the heart shows in-
flammatory activity the mitral valve.
................................................................................................
Table 1 A list of differential diagnoses to consider, in a
patient with valvulitis
Differential diagnosis: valvulitis:
Rare pathogens in infective endocarditis
• Human immunodeficiency virus (HIV)
• Syphilis
• Borrelia/Lyme disease





• Intracardiac tumour (e.g. fibroelastoma)
Rheumatic disorder
• Systemic lupus erythematosus (SLE)
with libman sacks endocarditis
• Anti-phospholipid syndrome





• Side-effect to DMARD-treatment












.refer to Table 2). Yet, repeated blood cultures were negative for bac-
terial and fungal growth. Also, the absence of an independent move-
ment of the vegetations was inconsistent with the classic findings in
infectious endocarditis. Since cardiac manifestations more commonly
occur in other systemic rheumatic diseases, the investigation included
an extensive autoimmune screen. Of particular interest was systemic
lupus erythematosus (SLE) with Libman-Sacks endocarditis.
However, the patient showed no skin manifestations. A skin biopsy
....................................................................................................................................................................................................................
Table 2 Overview of biochemical and microbiological blood tests in the patient
Laboratory findings/parameters Observed values Reference range
Complete blood count (CBC)
B-haemoglobin 7.4 mmol/L 7.3–9.5 mmol/L
B-thrombocytes 521  109/L 165–400  109/L
B-leukocytes 11.2  109/L 3.5–10.0  109/L
B-neutrophils 8.71  109/L 2.00–7.00  109/L
B-lymphocytes 2.01  109/L 1.30–3.50  109/L
B-monocytes 0.37  109/L 0.20–0.70  109/L
B-eosinophils 003  109/L <0.05  109/L
B-basophils 0.06  109/L <0.10  109/L
Kidney function
P-creatinine 88 mmol/L 45–90 mmol/L
eGFR/1.73 m2 69 mL/min >60 mL/min
P-calcium 2.47 mmol/L 2.20–2.55 mmol/L
P-albumin 34 g/L 36–45 g/L
Liver function
P-alanine aminotransferase 28 U/L 10–45 U/L
P-alkaline phosphatase 106 U/L 35–105 U/L
Inflammatory markers
C-reactive protein 26.7 mg/L <8.0 mg/L
P-procalcitonin <0.1 mg/L <0.5 mg/L
P-complement C3c 1.35 g/L 0.90–1.80 g/L
P-complement C4 0.19 g/L 0.10–0.40 g/L
P-immunglobulin A 4.33 g/L 0.80–3.90 g/L
P-immunglobulin G 9.9 g/L 6.9–15.7 g/L
P-immunglobulin M 1.03 g/L 0.55–2.3 g/L
Rheumatoid factor (IgM) 27 kiU/L < 20 kiU/L
Autoantibodies
Anti-cyclic citrullinated peptide antibodies (ACPA) IgG 1  103 arb. unit/L <10 arb. unit/L
Anti-nuclear antibody (ANA) Negative
Anti-double stranded DNA (IgG) 1  103 IU/L <10 IU/L
Anti-Smith antibody (IgG) <10.0 <10.0
P-Sjøgrens syndrom (SSA)-antibodies (IgG) <10.0 kiU/L <10.0 kiU/L
P-proteinase 3-Ab(IgG)(PR3) 14.0 kiU/L <2.0 kiU/L
C-ANCA (IgG) Positive
Serological tests for infection
Human parvovirus B19-Ab Negative
P-bartonella-Ab Negative
Human immunodeficiency virus 1þ 2 (HIV)-Ab Negative
P-Coxiella burnetii-Ab Negative
P-syfillis screen (Treponema pallidum-Ab) Negative




Monoclonal protein Not detected
Angiotensin-converting enzyme 50 U/L 12–60 U/L



























































of the abdomen was without lupus stigmata. There was no history of
anaemia or lymphopenia. Also, no anti-nuclear antibodies, anti-
double stranded DNA antibodies, anti-phospholipid antibodies, or
systemic complement depletion were detected. Surprisingly, the
blood tests showed the presence of cytoplasmic antineutrophil cyto-
plasmic antibodies (c-ANCA) and PR3 antibodies. Thus, the patient
was examined for granulomatosis with polyangiitis (GPA). There
were no upper respiratory tract symptoms, pulmonary infiltrations,
renal involvement, or neuropathy. A CT-scan of the sinonasal region
showed no inflammatory activity. A biopsy from the maxillary sinus
was without signs of inflammation, vasculitis, and granulomas.
Secondary amyloidosis was considered, but a subcutaneous abdom-
inal fat biopsy was without deposition of amyloid. The occurrence of
valvulitis as a paraneoplastic phenomenon in association with cancer
was suspected. But, clinically the patient did not have a fever, night
sweats, or weight loss. Lymphoma was ruled out by normal haema-
tology and a FDG-PET/CT-scan with no evidence of activity in the re-
ticuloendothelial system or occult malignancy. After all, the cardiac
findings were considered consistent with severe inflammatory activity
and EAM, secondary to RA. The immunosuppressive treatment was
intensified, and the patient started therapy with Rituximab (monoclo-
nal anti-CD20 antibody). At follow-up 3 months later, the echocar-
diographic evaluation showed regression in the valve lesions, and
normalization of C-reactive protein (Figure 3). Unfortunately, regres-
sion in the valve lesions, and fibrotic changes led to further dysfunc-
tion of the valve with the development of severe mitral regurgitation.
The patient now experienced progressively worsening in dyspnoea
(NYHA III) and was scheduled for mechanical mitral valve replace-
ment. Histological examination of the excised valve revealed severe
inflammation with infiltration of T-cells. Furthermore, many IgG4
positive plasma cells were detected, which raised suspicion of IgG4-
related disease. No granulomas were detected. No bacterial or fungal
growth was found. At the last follow-up visit in September 2020,
echocardiography showed the normal function of the mechanical
valve and normal left ventricular ejection fraction. Physical examin-
ation was unremarkable and the patient was asymptomatic.
Discussion
This case illustrates how EAMs in RA remain a diagnostic chal-
lenge. There is no agreed classification for EAMs symptoms may
mimic other disorders such as infections, malignancies, and other
rheumatic diseases. Extra-articular manifestations are associated
with active RA, and reviewing the existing literature, we have only
identified two cases of EAMs in patients with RA in the absence of
joint symptoms.8,9 Cardiovascular EAMs are often clinically silent
and rarely need treatment. To our knowledge, we are the first to
report a case of severe mitral valvulitis as an EAM in RA. The pa-
tient underwent a comprehensive examination before mitral valve
surgery. Histological analysis of the excised tissue raised further
questions concerning the diagnosis leading to yet another re-
evaluation of the patient. Infections and malignancies were ruled
out. PR3-ANCA-associated vasculitis could not entirely be ruled
out as the cause for valvulitis. But histology was without granulo-
mas or other signs of vasculitis. Thus, the patient did not meet the
classification criteria for GPA and the diagnosis was considered
highly unlikely. Suspicion of the rare IgG4 related disease was
raised due to histological findings. However, co-existence of IgG4
related disease and RA is only scarcely described in the litera-
ture,10 and there were no symptoms or organ involvement match-
ing the traditional localizations of IgG4-related disease.11,12 An
isolated IgG4 attack on the mitral valve was considered unlikely.
Before presentation with mitral valvulitis, the patient had already
exhibited two EAMs of RA; scleritis and heart block, despite on-
going anti-rheumatic treatment. We therefore believe that this
case represents a severe manifestation of seropositive RA, where
the dominating problem is aggressive and uncontrolled EAMs.
Figure 3 Transoesophageal echocardiogram of the mitral valve at follow-up visit 3 months later, after rituximab treatment. Images show regres-
sion in the valve lesions and development of severe mitral regurgitation due to fibrotic changes of the valve.



























































This case demonstrates a rare manifestation of RA with mitral valvul-
itis and highlights the importance of extensive clinical examination in
challenging patients, where re-evaluation of the disease always must
be considered. There is no consensus regarding the treatment of
valvulitis in the setting of RA. In patients, where the extra-articular
disease is the dominating problem, we suggest a more aggressive
treatment strategy.
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